Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study

Basit Öğe Kaydı
dc.authorid0000-0001-7858-8180en_US
dc.contributor.authorYasin, Ayşe İrem
dc.contributor.authorAydın, Sabin Göktaş
dc.contributor.authorSümbül, Bilge
dc.contributor.authorKoral, Lokman
dc.contributor.authorŞimşek, Melih
dc.contributor.authorGeredeli, Çağlayan
dc.contributor.authorKalkan, Ziya
dc.date.accessioned2023-03-13T06:53:46Z
dc.date.available2023-03-13T06:53:46Z
dc.date.issued2022en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Medikal Onkoloji Ana Bilim Dalıen_US
dc.description.abstractAim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-cancer volunteers. An IgG level >= 50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: ClinicalTrials.gov) Plain language summary Cancer patients are at high risk for infection with SARS-CoV-2 and of developing the associated disease, COVID-19, which therefore puts them in the priority group for vaccination. This study evaluated the efficacy and safety of CoronaVac, an inactivated virus vaccine, in cancer patients. The immune response rate, defined as seropositivity, was 85.2% in the cancer patient group and 97.5% in the control group. The levels of antibodies, which are blood markers of immune response to the vaccine, were also significantly lower in the patient group, especially in those older than 60 years and receiving chemotherapy. These results highlight the importance of determining the effective vaccine type and dose in cancer patients to protect them from COVID-19 without disrupting their cancer treatment.en_US
dc.identifier.citationYasin, A.İ., Aydın, S.G., Sümbül, B., Koral, L., Şimşek, M., Geredeli, C. ve diğerleri. (2022). Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study. Future Oncology, 18(10), 1235-1244.en_US
dc.identifier.doi10.2217/fon-2021-1248
dc.identifier.endpage1244en_US
dc.identifier.issn1479-6694
dc.identifier.issn1744-8301
dc.identifier.issue10en_US
dc.identifier.pmid35081732
dc.identifier.scopusScopusIdYok
dc.identifier.scopusqualityQ2
dc.identifier.startpage1235en_US
dc.identifier.urihttps://www.futuremedicine.com/doi/epub/10.2217/fon-2021-1248
dc.identifier.urihttps://hdl.handle.net/11468/11369
dc.identifier.volume18en_US
dc.identifier.wosWOS:000747186600001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKalkan, Ziya
dc.language.isoenen_US
dc.publisherFuture Medicine LTD.en_US
dc.relation.ispartofFuture Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCanceren_US
dc.subjectChemotherapyen_US
dc.subjectCoronaVacen_US
dc.subjectCOVID-19en_US
dc.subjectCOVID-19 vaccinesen_US
dc.subjectImmunotherapyen_US
dc.subjectMalignancyen_US
dc.subjectSARS-CoV-2en_US
dc.titleEfficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort studyen_US
dc.titleEfficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Efficacy and safety profile of COVID-19 vaccine in cancer patients a prospective, multicenter cohort study.pdf
Boyut:
1.37 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu